As therapeutic uses of anti-PD-1/PD-L1 antibodies, anti-CLTA-4 antibodies, and CAR-T cell therapy have increasingly been approved in recent years in Japan and many other countries, immunotherapy has become established as one of the standard therapies for treating cancer.
These therapies have shown therapeutic effects with improved prognosis in many cases that could not be treated with conventional therapies.
However, more than half of the cases still do not respond to cancer immunotherapy. Some of the issues that need to be addressed are as follows:
- 1) Clarification of the mechanisms of unresponsiveness
- 2) Development of combination therapy to enhance therapeutic effects
- 3) Development of biomarkers to predict therapeutic efficacy
- 4) Mechanistic analysis of immune-related adverse events (autoimmune diseases)
While addressing these issues, the Center for Cancer Immunotherapy and Immunobiology aims to recruit worldwide and foster the next generation of highly skilled researchers in cancer, immunization, and various other fields who can contribute to further development in the field of human cancer immunology.